At Siemens Healthineers, our purpose is to enable healthcare providers to increase value by empowering them on their journey toward expanding precision medicine, transforming care delivery, and improving patient experience, all made possible by digitalizing healthcare.

An estimated 5 million patients globally benefit every day from our innovative technologies and services in the areas of diagnostic and therapeutic imaging, laboratory diagnostics, and molecular medicine, as well as digital health and enterprise services.

We are a leading medical technology company with over 120 years of experience and 18,000 patents globally. Through the dedication of more than 50,000 colleagues in 75 countries, we will continue to innovate and shape the future of healthcare.

VERSANT and all associated marks are trademarks of Siemens Healthcare Diagnostics Inc., or its affiliates. All other trademarks and brands are the property of their respective owners.

The VERSANT HCV Genotype 2.0 Assay (LiPA) is a line probe assay, for in vitro diagnostic use, which identifies Hepatitis C virus (HCV) genotypes 1 to 6 and subtypes 1a and 1b in human serum or plasma (K2EDTA, ACD-A, CPD, and CPDA) samples. The VERSANT HCV Genotype 2.0 Assay (LiPA) is intended to be used as an aid in the management of patients with chronic HCV infection to guide the selection of antiviral treatment. The VERSANT HCV Genotype 2.0 Assay (LiPA) is not approved for use as a donor screening test for HCV or as a diagnostic test to confirm the presence of HCV.

FDA-approved in the U.S.
Optimize your laboratory’s testing with the widely used VERSANT® HCV Genotype 2.0 Assay (LiPA). LiPA utilizes reverse-hybridization technology to detect HCV genotypes 1–6 and subtypes 1a and 1b. LiPA provides highly accurate identification of HCV genotypes and subtypes for optimal and personalized patient therapy.

LiPA results help guide antiviral therapy in patients with chronic hepatitis C virus (HCV) infection as well as determine duration and dosage of therapy. The LiPA assay analyzes variations in the 5’ untranslated region (5’ UTR) and core region to improve accuracy and provide more precise distinction between subtypes 1a and 1b.

- Highly effective HCV treatment regimens including direct-acting antiviral agents (DAA) are now available. These regimens can impact the rate of cured infections.
- Testing for HCV genotype is recommended to guide selection of the most appropriate antiviral regimen. *
- With certain regimens, patients infected with subtype 1a may have higher rates of virologic failure than those infected with subtype 1b.*

Flexible laboratory solutions—only from Siemens Healthineers

1. **Extraction**
   High-quality RNA for genotyping.

   **Optimized Extraction Method**
   - Efficient automated extraction using the VERSANT kPCR Sample Prep with the MiPLX Software Solution

2. **Amplification**
   Easy-to-use, one-step RT-PCR master mix configuration amplifies HCV targets.

   **Amplification and Detection Flexibility**
   - Adaptable to most laboratory-validated thermal cyclers
   - Simultaneous amplification of HCV 5' UTR and core region for accurate detection of genotypes 6 (c~i) and subtypes 1a vs. 1b

3. **Genotyping**
   Reverse hybridization technology using 22 genotype- and subtype-specific probes.

   **Scalable Strip Processing**
   - Automated AutoBlot 3000H Genotyping Instrument (processes up to 20 samples per run)
   - Automated Auto-LiPA 48 Genotyping Instrument (processes up to 48 samples per run)

4. **Interpretation**
   Genotype and subtype determined from the band pattern using an interpretation chart.

   **Result Interpretation Options**
   - Visual or software-based interpretation of results
   - Easy-to-use interpretation chart
   - Multiple software features and bidirectional LIS compatibility for management of results data

1. Contact your regional sales representative for more information on this option.
Perform HCV genotyping and subtyping with greater accuracy

Proven technology, optimized assays.

Based on sequences from the core region and the 5' UTR, the VERSANT HCV Genotype 2.0 Assay (LiPA) uses reverse hybridization technology to provide accurate identification of HCV genotype- and subtype-specific data for optimal patient therapy.

• Identification of genotypes 1–6 and subtypes 1a and 1b
• Analysis of 5' UTR and core regions
• Highly accurate differentiation of subtypes 1a vs. 1b
• Easy-to-use interpretation chart

Optimize your HCV testing efficiency with LiPA

VERSANT LiPA Strips provide convenient and easy interpretation.

Hepatitis C Viral RNA Genome
Target: HCV 5' UTR and Core Region

5' UTR

Structural Proteins
Nonstructural Proteins

3' UTR

5'

Core
E1
E2
p7
NS2
NS3
NS4A
NS4B
NS5A
NS5B

3'

Open Reading Frame

ORDERING INFORMATION

<table>
<thead>
<tr>
<th>Systems</th>
<th>Catalog No.</th>
<th>Product Name</th>
<th>No. of Tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Auto-LiPA 48 Genotyping Instrument</td>
<td>10313066</td>
<td>Auto-LiPA 48 Genotyping Instrument</td>
<td>48 Tests/Run</td>
</tr>
<tr>
<td>AutoBlot 3000H Genotyping Instrument</td>
<td>10315618</td>
<td>AutoBlot 3000H Genotyping Instrument</td>
<td>20 Tests/Run</td>
</tr>
<tr>
<td>VERSANT kPCR Sample Prep</td>
<td>10282928</td>
<td>VERSANT kPCR Sample Prep</td>
<td>1 Unit</td>
</tr>
<tr>
<td>VERSANT kPCR SP Workstation Kit</td>
<td>10702391</td>
<td>VERSANT kPCR SP Workstation Kit</td>
<td>1 Unit</td>
</tr>
<tr>
<td>VERSANT HCV Genotype 2.0 Assay</td>
<td>10492004</td>
<td>VERSANT HCV Genotype 2.0 Assay</td>
<td>40 Tests</td>
</tr>
<tr>
<td>VERSANT HCV Genotype 2.0 Assay</td>
<td>10492005</td>
<td>VERSANT HCV Genotype 2.0 Assay</td>
<td>100 Tests</td>
</tr>
<tr>
<td>VERSANT HCV Amplification 2.0 Kit</td>
<td>10719666</td>
<td>VERSANT HCV Amplification 2.0 Kit</td>
<td>40 Tests</td>
</tr>
<tr>
<td>VERSANT HCV Amplification 2.0 Kit</td>
<td>10719667</td>
<td>VERSANT HCV Amplification 2.0 Kit</td>
<td>100 Tests</td>
</tr>
<tr>
<td>VERSANT HCV Control 2.0 Kit</td>
<td>10719668</td>
<td>VERSANT HCV Control 2.0 Kit</td>
<td>6 Tests</td>
</tr>
<tr>
<td>VERSANT Sample Preparation 1.0 Reagents Kit</td>
<td>10286026</td>
<td>VERSANT Sample Preparation 1.0 Reagents Kit</td>
<td>Box 1</td>
</tr>
<tr>
<td>VERSANT Sample Preparation 1.0 Reagents Kit</td>
<td>10286027</td>
<td>VERSANT Sample Preparation 1.0 Reagents Kit</td>
<td>Box 1</td>
</tr>
<tr>
<td>LiPA-Scan HCV IVD Software V1.00</td>
<td>10492006</td>
<td>LiPA-Scan HCV IVD Software V1.00</td>
<td>1 Unit</td>
</tr>
<tr>
<td>LiPA SP 2.0 Software Installation Kit</td>
<td>10817497</td>
<td>LiPA SP 2.0 Software Installation Kit</td>
<td>1 Unit</td>
</tr>
<tr>
<td>Scanner, LiPA-Scan-verified (110 V)</td>
<td>10322207</td>
<td>Scanner, LiPA-Scan-verified (110 V)</td>
<td>1 Unit</td>
</tr>
</tbody>
</table>

Siemens Healthineers offers laboratories a complete and flexible HCV genotyping solution matched to your testing volume.

Take the Next Step

Contact your local Siemens Healthineers representative to learn more or visit siemens-healthineers.com/molecular-diagnostics.